Drug intelligence / Profile preview

AMB402

Development stage: Preclinical
Lead developer: Aimed Bio
Modality: Small Molecules
Administration: Intravenous

Overview

AMB402 is a camptothecin-derived topoisomerase I inhibitor payload developed by Aimed Bio in collaboration with GeneQuantum Healthcare. It is designed as a platform payload for use in antibody-drug conjugates (ADCs) rather than as a standalone therapeutic candidate. The molecule functions by inhibiting DNA topoisomerase I, which prevents the religation of DNA strands during replication, leading to double-strand breaks and subsequent apoptosis in tumor cells. AMB402 is a key component of Aimed Bio's ADC platform and is utilized in candidates such as AMB303, which is co-developed with Samsung Biologics. It is currently in the preclinical stage for the treatment of various solid tumors.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on AMB402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMB402.

Explore the full profile